Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion

COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second upd...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Ahmad, Noun, Peter, Khalil, Charbel, Taher, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006377/
https://www.ncbi.nlm.nih.gov/pubmed/33791197
http://dx.doi.org/10.3389/fonc.2021.564383
_version_ 1783672303415984128
author Ibrahim, Ahmad
Noun, Peter
Khalil, Charbel
Taher, Ali
author_facet Ibrahim, Ahmad
Noun, Peter
Khalil, Charbel
Taher, Ali
author_sort Ibrahim, Ahmad
collection PubMed
description COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies.
format Online
Article
Text
id pubmed-8006377
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80063772021-03-30 Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion Ibrahim, Ahmad Noun, Peter Khalil, Charbel Taher, Ali Front Oncol Oncology COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8006377/ /pubmed/33791197 http://dx.doi.org/10.3389/fonc.2021.564383 Text en Copyright © 2021 Ibrahim, Noun, Khalil and Taher. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ibrahim, Ahmad
Noun, Peter
Khalil, Charbel
Taher, Ali
Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
title Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
title_full Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
title_fullStr Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
title_full_unstemmed Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
title_short Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
title_sort changing management of hematological malignancies with covid-19: statement and recommendations of the lebanese society of hematology and blood transfusion
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006377/
https://www.ncbi.nlm.nih.gov/pubmed/33791197
http://dx.doi.org/10.3389/fonc.2021.564383
work_keys_str_mv AT ibrahimahmad changingmanagementofhematologicalmalignancieswithcovid19statementandrecommendationsofthelebanesesocietyofhematologyandbloodtransfusion
AT nounpeter changingmanagementofhematologicalmalignancieswithcovid19statementandrecommendationsofthelebanesesocietyofhematologyandbloodtransfusion
AT khalilcharbel changingmanagementofhematologicalmalignancieswithcovid19statementandrecommendationsofthelebanesesocietyofhematologyandbloodtransfusion
AT taherali changingmanagementofhematologicalmalignancieswithcovid19statementandrecommendationsofthelebanesesocietyofhematologyandbloodtransfusion

Ejemplares similares